Brian A. McKittrick
Drew University(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Receptor Mechanisms and Signaling, Chemical Synthesis and Analysis, Cholinesterase and Neurodegenerative Diseases, Alzheimer's disease research and treatments
Most-Cited Works
- → Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases(2010)175 cited
- → Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitor(2012)151 cited
- → Discovery of Cyclic Acylguanidines as Highly Potent and Selective β-Site Amyloid Cleaving Enzyme (BACE) Inhibitors: Part I—Inhibitor Design and Validation(2009)121 cited
- → Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical Library Design to Identify Novel μM Leads for the Development of nM BACE-1 (β-Site APP Cleaving Enzyme 1) Inhibitors(2009)102 cited
- → Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction(2012)99 cited
- → Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity(1997)80 cited
- → Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2(2007)65 cited
- → Syn-stereoselective epoxidation of allylic ethers using CF3CO3H.(1985)58 cited
- → Advances in the chemistry of 2,3-epoxyalcohols. New methodology for contra-trans-diaxial opening and selective enediol oxidation(1985)56 cited
- → Design and Validation of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (BACE1) Inhibitors: Conformational Constraint to Favor a Bioactive Conformation(2012)56 cited